Dunad Therapeutics, established in 2020 and headquartered in Cambridge, UK, is a pioneering biopharmaceutical company specializing in the development of targeted oral protein degradation therapies. Utilizing a unique small molecule platform, Dunad achieves the targeted degradation of disease-causing proteins, including traditionally challenging and undruggable targets. The platform's tunable and highly selective molecular approach sets it apart, offering a target-class agnostic mechanism distinct from other protein degradation technologies. With operations spanning the UK and North America, Dunad is strategically positioned to expand its emerging pipeline, primarily focused on oncology and CNS indications. The company's innovative strides are supported by Epidarex Capital, BioGeneration Ventures, and Novartis, with whom Dunad announced a strategic partnership in November 2021, further propelling the development of next-generation oral covalent and protein degrading small molecule drugs.